JT-21

JT-21 is a small molecule curcumin analog being developed by Canget BioTekpharma for the treatment of various solid tumors, including ovarian, lung, and colon cancers. As a derivative of curcumin, it is designed to improve upon the parent compound's pharmacological profile, such as bioavailability and potency. While the specific molecular targets for JT-21 have not been explicitly detailed in public pipeline disclosures, curcumin analogs typically exert anti-tumor effects by modulating multiple signaling pathways involved in cell proliferation and apoptosis, such as NF-κB and STAT3. The program is currently in the in vitro/preclinical stage of development.

Other names

JT-21JT21JT 21